Clinical trials
High-Risk Cancer clinical trials
Below are recruiting high-risk cancer clinical trials, each written for real people, not researchers. We’re tracking 396 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06818682RecruitingPhase 2
Shortened hormone therapy with radiation for high-risk prostate cancer
This trial tests whether a shorter course of hormone therapy (2 years) plus a new hormone drug (6 months) with radiation is as effective as longer treatment for high-risk prostate cancer that hasn't spread.
Mumbai, MaharashtraAges 19–99 - NCT07366112RecruitingPhase 2
CDK4/6 inhibitor plus hormone therapy before breast cancer surgery
This trial tests a combination of a CDK4/6 inhibitor (a type of targeted therapy) with hormone therapy given before surgery for early-stage breast cancer that is hormone receptor-positive and HER2-negative. It aims to see if this approach can shrink tumors and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT07357259Recruiting
Delayed pelvic scan with PSMA PET/CT for high-risk prostate cancer
This trial uses a special PET/CT scan with a radioactive tracer (PSMA) to get detailed images of the pelvis in men with high-risk prostate cancer. The goal is to improve cancer staging and detect recurrence more accurately.
Bologna, ItalyAges 30 years+ - NCT07358715Recruiting
Liquid biopsy to improve lung cancer screening
This study tests whether a simple blood test (liquid biopsy) can help find lung cancer earlier in people at high risk. It also includes people already diagnosed with lung cancer to refine the test.
SingaporeAges 21–75 - NCT06565247RecruitingPhase 3
Comparing PET and MRI scans before prostate cancer surgery
This trial tests if a special PET scan (PSMA-PET) plus MRI is better than MRI alone at finding the full extent of high-risk prostate cancer before surgery. It aims to improve surgical planning by checking scan results against the removed prostate tissue.
MalmöAges 18 years+ - NCT07343349Recruiting
Adding a higher radiation dose to prostate tumors during standard radiotherapy
This trial tests whether giving an extra, focused dose of radiation to the visible tumor inside the prostate can improve results for men with intermediate or high-risk prostate cancer that has not spread. The total treatment is given in 12 or 20 sessions.
AarhusAges 18 years+ - NCT07325721RecruitingPhase 2
Shorter radiation with a focused boost for high-risk prostate cancer
This trial tests a shorter course of radiation therapy with an extra 'boost' to the most aggressive part of the tumor, combined with hormone therapy, for men with high-risk or locally advanced prostate cancer that has not spread outside the pelvis.
Charleston, South CarolinaAges 18 years+ - NCT07316361Enrolling by invitationEarly Phase 1
Personalized vaccine for high-risk endometrial cancer
This trial tests a personalized vaccine made from your tumor's unique proteins to help your immune system fight high-risk or advanced endometrial cancer. It is given along with your regular cancer treatments.
Thessaloniki, ThessalonikiAges Any age - NCT07322263RecruitingPhase 2
Gemcitabine and docetaxel for bladder cancer that returned after BCG
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
Iowa City, IowaAges 18–99 - NCT07324096Recruiting
Screening for pancreatic cancer in people with new diabetes
This study screens people with recent diabetes who are at high risk for pancreatic cancer. It uses a CT scan to find cancer early, when it may be easier to treat.
Rochester, MinnesotaAges 50–85 - NCT07311577RecruitingPhase 2
Trial of a drug combo for HER2-positive ovarian cancer
This trial tests a combination of disitamab vedotin, platinum chemotherapy, and bevacizumab as first treatment for high-risk ovarian cancer that has a protein called HER2. The goal is to see if this therapy helps control the cancer and keeps it from growing.
Nanjing, JiangsuAges 18–75 - NCT07307560Recruiting
High-flow oxygen during sedation for sleep apnea patients having endoscopy
This study tests if high-flow nasal oxygen can prevent oxygen drops during sedated endoscopy in patients with severe obstructive sleep apnea. It may help people who are at higher risk of breathing problems during the procedure.
Hangzhou, ZhejiangAges 18 years+ - NCT07279077RecruitingPhase 2
Low-dose radiation with chemo and immunotherapy for high-risk colon cancer
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of high-risk colon cancer that has not spread. The goal is to see if this approach can shrink the tumor before surgery and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06889623Recruiting
Chemotherapy right after surgery for high-risk bladder cancer
This trial tests whether giving chemotherapy immediately after surgery can help people with high-risk, non-muscle-invasive bladder cancer. It aims to reduce the chance of the cancer coming back.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07262840Recruiting
Health behavior change for people at high risk for colorectal cancer
This trial tests a program to help people at high risk for colorectal cancer change their health behaviors to lower their risk. It might help you if you are worried about your risk and want to make positive changes.
Shenyang, LiaoningAges 1.5 years–6.7 years - NCT07242352RecruitingPhase 3
Comparing elacestrant to standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy drug called elacestrant against standard hormone treatments for people with a specific type of early breast cancer (ER+/HER2-) that has a high chance of coming back. The goal is to see if elacestrant works better at keeping the cancer from returning.
Mannheim, Baden-WurttembergAges 18 years+ - NCT06607757RecruitingPhase 2
Capivasertib plus fulvestrant for high-risk lobular breast cancer
This trial tests adding capivasertib to fulvestrant for women with a certain type of breast cancer (invasive lobular carcinoma) that is hormone-receptor positive and has a high risk of coming back. The treatment is given before surgery to see if it works better than fulvestrant alone.
AugsburgAges 18 years+ - NCT07230639RecruitingPhase 2
Shorter radiation with chemo and immunotherapy for high-risk colon cancer
This trial tests a shorter course of radiation combined with chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of high-risk colon cancer that has not spread. The goal is to see if this approach can shrink the tumor before surgery and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT07239245RecruitingPhase 2
TACE plus immunotherapy for high-risk liver cancer before surgery
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
Beijing, Beijing MunicipalityAges 18–75 - NCT07237230Recruiting
Gamma-delta T cells to prevent leukemia relapse after transplant
This trial tests if a special type of immune cell called gamma-delta T cells can help prevent acute myeloid leukemia from coming back after a stem cell transplant. It is for people with high-risk features who have recently had a transplant.
Wuhan, HubeiAges 18–65 - NCT07226544RecruitingPhase 2
Ivonescimab before surgery for high-risk kidney cancer
This trial tests giving the drug ivonescimab before surgery for patients with high-risk clear cell kidney cancer. The goal is to see if it can help shrink the tumor and improve outcomes.
Duarte, CaliforniaAges 18 years+ - NCT07219303Recruiting
Adaptive radiation therapy for intermediate- or high-risk prostate cancer
This trial tests a type of radiation that adjusts to changes in your prostate during treatment. It aims to improve accuracy and reduce side effects for men with intermediate- or high-risk prostate cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07207824RecruitingPhase 3
Study of a new drug for high-risk bladder cancer
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07208240RecruitingPhase 1/Phase 2
PSMA-targeted radiation before prostate removal for advanced cancer
This trial tests giving a radioactive drug (PSMA-targeted) before surgery for prostate cancer that has spread locally but not to other parts of the body. The goal is to see if it helps lower the risk of the cancer coming back.
Petah TikvaAges 18 years+
Hear when a new High-Risk Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high-risk cancer?
- Yes. Clin2 currently lists 396 recruiting high-risk cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high-risk cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high-risk cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.